Bidirectional Dysregulation of AMPA Receptor-Mediated Synaptic Transmission and Plasticity in Brain Disorders by Zhang, Hongyu & Bramham, Clive R.
MINI REVIEW




University of Coimbra, Portugal
Reviewed by:
Graham Hugh Diering,
University of North Carolina at Chapel
Hill, United States
Marina E. Wolf,













Received: 26 March 2020
Accepted: 28 May 2020
Published: 10 July 2020
Citation:
Zhang H and Bramham CR
(2020) Bidirectional Dysregulation of
AMPA Receptor-Mediated Synaptic
Transmission and Plasticity in Brain
Disorders.




Transmission and Plasticity in
Brain Disorders
Hongyu Zhang*†‡ and Clive R. Bramham*†
Department of Biomedicine, University of Bergen, Bergen, Norway
AMPA receptors (AMPARs) are glutamate-gated ion channels that mediate the majority of
fast excitatory synaptic transmission throughout the brain. Changes in the properties and
postsynaptic abundance of AMPARs are pivotal mechanisms in synaptic plasticity, such
as long-term potentiation (LTP) and long-term depression (LTD) of synaptic transmission.
A wide range of neurodegenerative, neurodevelopmental and neuropsychiatric disorders,
despite their extremely diverse etiology, pathogenesis and symptoms, exhibit brain
region-specific and AMPAR subunit-specific aberrations in synaptic transmission or
plasticity. These include abnormally enhanced or reduced AMPAR-mediated synaptic
transmission or plasticity. Bidirectional reversal of these changes by targeting AMPAR
subunits or trafficking ameliorates drug-seeking behavior, chronic pain, epileptic seizures,
or cognitive deficits. This indicates that bidirectional dysregulation of AMPAR-mediated
synaptic transmission or plasticity may contribute to the expression of many brain
disorders and therefore serve as a therapeutic target. Here, we provide a synopsis of
bidirectional AMPAR dysregulation in animal models of brain disorders and review the
preclinical evidence on the therapeutic targeting of AMPARs.
Keywords: AMPA receptor (AMPAR), synaptic transmission and plasticity, AMPAR trafficking, neurodegenarative
diseases, neuropsychiatric disorders, neurodevelopmental disorders
INTRODUCTION
Synaptic plasticity is central to memory and other adaptive responses of adult neural circuits.
NMDA receptor (NMDAR)-dependent long-term potentiation (LTP) and long-term depression
(LTD) are triggered by the activation of NMDARs but expressed by an increase or decrease
in the abundance of AMPA receptors (AMPARs) at the postsynaptic membrane, respectively.
Postsynaptic LTD induced by the activation of group I metabotropic glutamate receptors (mGluR-
LTD) is similarly expressed by a reduction in the number of postsynaptic AMPARs (Luscher
and Huber, 2010). AMPARs are tetrameric complexes composed of GluA1, GluA2, GluA3, or
GluA4 subunits, with GluA1/2 heteromers dominant at hippocampal CA1 synapses. The number
and composition of postsynaptic AMPARs are in a dynamic balance, which is achieved by AMPAR
trafficking. AMPAR trafficking involves intracellular transport, endo-/exo-cytosis, recycling, lateral
surface diffusion, and degradation (Choquet, 2018). Newly synthesized receptors are transported
intracellularly on microtubules from soma to dendrites. Through exocytosis/endocytosis, AMPARs
cycle between intracellular and surface pools. Recycling refers to the process by which endocytosed
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receptors are returned to the cell surface via exocytosis.
Surface AMPARs exchange between synaptic and extrasynaptic
compartments via lateral diffusion and are reversibly trapped
at synapses by postsynaptic scaffold proteins, cytoskeletal
proteins, adhesion proteins, or extracellular matrix. This
continuous exchange of receptors between different pools
establishes a dynamic equilibrium (Figure 1, top panel).
This balance can be shifted in response to neuronal/synaptic
activity (Opazo and Choquet, 2011). For example, during LTP,
AMPARs are selectively recruited, by lateral diffusion, to the
postsynaptic membrane to increase synaptic strength, while
exocytosed AMPARs serve as an extrasynaptic reservoir (Makino
and Malinow, 2009; Penn et al., 2017). Conversely, during
LTD, AMPARs are dispersed, through endocytosis, from the
postsynaptic membrane to reduce synaptic transmission. Thus,
synaptic strength at single synapses is bidirectionally regulated
via AMPAR trafficking.
Increasing evidence shows that learning and memory can be
modified at the cellular andmolecular levels by acute modulation
of LTP, LTD, or AMPAR trafficking. For example, fear
memory established by associating a foot-shock with optogenetic
stimulation of auditory inputs to the amygdala was inactivated
by subsequent optogenetic delivery of LTD to the conditioned
auditory input and further reactivated by optogenetic delivery
of LTP (Nabavi et al., 2014). Moreover, PhotonSABER, an
optogenetic tool developed to inhibit AMPAR endocytosis
during LTD in a light-dependent manner, was applied in
Purkinje cells and inhibited cerebellar motor learning (Kakegawa
et al., 2018). Furthermore, immobilization of surface AMPARs
by crosslinking approaches markedly impaired hippocampal
LTP in vivo and also inhibited contextual fear conditioning
(Penn et al., 2017). These results support a causal contribution
of AMPAR trafficking and synaptic plasticity to learning and
memory. Second, they suggest that learning and memory can be
manipulated at the molecular level (AMPARs trafficking), as well
as at the cellular level by induction of LTP or LTD.
Notably, the dynamic equilibrium of AMPAR trafficking
can also be shifted under pathological conditions (Figure 1,
bottom left and bottom right panels). Increasing evidence
suggests that brain region-specific and AMPAR subunit-
specific aberrant enhancement or reduction in synaptic
transmission or plasticity occurs with many neurodegenerative,
neurodevelopmental, and neuropsychiatric disorders. A reversal
of these aberrations ameliorates drug-seeking behavior, chronic
pain, epileptic seizures, or cognitive deficits. Although the
etiology, pathogenesis, and symptoms vary greatly between
disorders, the observed restoration of function and mitigation
of symptoms suggest that dysregulation of AMPAR-mediated
synaptic transmission and plasticity is a convergence point for
multiple pathological pathways, rather than a compensatory
protective mechanism.
Below, we review the evidence of brain region-specific
and AMPAR subunit-specific bidirectional dysregulation of
AMAPR-mediated synaptic transmission and plasticity in animal
models of several of the most common neurodegenerative,
neurodevelopmental and neuropsychiatric disorders. We also
review the therapeutic effects exerted by targeting AMPAR
subunits or trafficking. We propose that, despite the highly
diverse underlying pathologies, dysregulation of AMPARs is a
common mechanism in the expression of different diseases,
and bidirectional therapeutic targeting of AMPARs may be a
promising mitigation strategy for various diseases. Lastly, we
discuss the potential therapeutic application of small interfering
peptides and aptamers, as well as the need for new optogenetic
and optopharmacological tools for elucidating the molecular
mechanisms and spatial-temporal dynamics of AMPA regulation
in animal models of brain disorders.
Addiction
Addiction is a psychological and physical inability to stop
consuming a chemical, despite adverse consequences. Many
addictive drugs induce changes in the synaptic composition of
AMPARs and alter synaptic plasticity within reward circuitry,
such as the ventral tegmental area (VTA), nucleus accumbens
(NAc), prefrontal cortex (PFC), dorsal medial striatum (DMS),
and amygdala (Ungless et al., 2001; Saal et al., 2003; Wolf,
2016; Cooper et al., 2017). These drugs include cocaine (Conrad
et al., 2008), delta(9)-tetrahydrocannabinol (Good and Lupica,
2010), methamphetamine (Scheyer et al., 2016), amphetamine
(Saal et al., 2003), benzodiazepines (Tan et al., 2010), nicotine
(Marchi et al., 2015), morphine (Madayag et al., 2019), heroin
(Van den Oever et al., 2008), and alcohol (Ma et al., 2018).
For instance, cocaine exposure or self-administration induced
silent synapses, which do not contain AMPARs but only
NMDARs, in NAc (Ma et al., 2014; Huang et al., 2015).
However, extended withdrawal (e.g., 30–45 days) from cocaine
self-administration resulted in the unsilencing of synapses
via the synaptic insertion of Ca2+-permeable (CP) GluA2-
lacking AMPARs. This indicated that CP-AMPARs do not
primarily mediate drug-seeking per se, but rather contribute
to withdrawal-dependent enhancement (incubation) of cocaine-
seeking behavior (Conrad et al., 2008; Lee et al., 2013; Ma
et al., 2014; Scheyer et al., 2016). Optogenetically induced
LTD resulting in CP-AMPAR removal from amygdala-to-NAc
synapses attenuated incubation of cocaine craving (Lee et al.,
2013). Besides, the application of a mGluR1 positive allosteric
modulator, by removing CP-AMPARs from NAc synapses, also
reduced the expression of incubated cocaine craving (Loweth
et al., 2014). Further evidence suggested that, depending on
the input pathway, synaptic insertion of non-CP-AMPARs also
underlies cocaine-seeking behavior. In one study, extended
cocaine withdrawal evoked the insertion of CP-AMPARs in NAc
synapses receiving input from medial PFC, whereas non-CP-
AMPARs were inserted at synapses with input from the ventral
hippocampus. Optogenetic reversal of plasticity at both inputs
abolished cocaine seeking (Pascoli et al., 2014). In another study,
extended cocaine withdrawal induced CP-AMPAR insertion in
NAc synapses with infralimbic (IL) mPFC input, whereas non-
CP-AMPARs were inserted at synapses with prelimbic (PrL)
mPFC input. Optogenetic reversal of the plasticity of IL-to-NAc
and PrL- to-NAc projections enhanced and reduced, respectively,
incubation of cocaine craving (Ma et al., 2014), suggesting
a circuit-dependent mechanism. Moreover, optogenetic LTP
and LTD induction at projections from mPFC to DMS
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FIGURE 1 | AMPAR trafficking under physiological and pathological conditions and AMPAR-based therapeutic strategies. Top panel, basal condition. AMPARs
constitutively cycle between intracellular pools and the neuronal surface via endocytosis and exocytosis. At the plasma membrane, AMPARs bidirectionally exchange
between extrasynaptic and synaptic compartments by lateral diffusion, powered by thermal agitation. This is readily perturbed by protein-protein interactions at
postsynaptic sites, where AMPARs are trapped by reversible binding to postsynaptic density (PSD) proteins, cytoskeletal proteins, adhesion proteins, or extracellular
matrix. The dynamic equilibrium established between different pools allows the steady state levels of AMPARs at synapses. Bottom left panel, pathological
conditions, such as addiction, stress/depression, chronic pain, and epilepsy. The equilibrium is shifted towards the accumulation of postsynaptic AMPARs
in a region/circuit-specific and subunit-specific manner. This may be due to the enhanced diffusion trapping mechanisms and/or potentiated exocytosis (Red).
AMPAR lateral diffusion mediates the recruitment of extrasynaptic AMPARs to the postsynaptic membrane. AMPAR-based therapeutic strategies, which ameliorate
drug-seeking behavior, chronic pain, or epileptic seizures in corresponding animal models, include reducing diffusion trapping and/or enhancing endocytosis (such
as with optogenetic LTD induction or mGluR1 positive allosteric modulator), or inhibiting AMPAR-mediated currents by AMPAR antagonists. Bottom right panel,
pathological conditions, such as Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and fragile X syndrome (FXS). The equilibrium is
shifted towards the dispersal of AMPARs from the postsynaptic membrane in hippocampal and cortical neurons, which is linked to cognitive deficits, likely through the
impairment of diffusion trapping mechanisms resulting in an increase in AMPAR lateral diffusion, potentiation of endocytosis, and/or suppression of exocytosis (Red).
AMPAR-based therapeutic strategies, which improve synaptic plasticity and/or memory in animal models of HD, AD and FXS, include enhancing diffusion trapping
mechanisms (such as with tianeptine), blocking endocytosis (such as with mGluR5 antagonists), or enhancing AMPAR function (such as with AMPAR positive allosteric
modulators)(Blue). However, the effects of these strategies in human patients remain to be determined. Brain region- and AMPAR subunit-specific treatment is needed.
increased and decreased alcohol-seeking behavior, respectively
(Ma et al., 2018). Furthermore, microinjection of NASPM, a
synthetic analog of Joro spider toxin that selectively inhibits
homomeric GluA1-AMPARs (CP-AMPARs), into the central
nucleus of the amygdala, reduced morphine intake of rats
(Hou et al., 2020).
Clathrin- and GluA2-dependent AMPAR endocytosis
appears to play a crucial role in D-amphetamine-induced
behavioral sensitization (Brebner et al., 2005; Choi et al., 2014),
morphine-induced place preference (Dias et al., 2012) and
cue-induced reinstatement of heroin self-administration (Van
den Oever et al., 2008). Blocking regulated AMPAR endocytosis
and LTD by GluA2-derived peptide (Tat-GluA23Y) prevented
the expression and maintenance of D-amphetamine-induced
behavioral sensitization (Brebner et al., 2005; Choi et al., 2014),
facilitated the extinction of morphine-induced conditioned
place preference (Dias et al., 2012), and reduced heroin seeking
(Van den Oever et al., 2008). Collectively, these results suggest
a critical role for AMPAR trafficking and AMPAR-mediated
plasticity in addictive behavior. Targeting AMPAR subunits
or AMPAR trafficking may represent a therapeutic strategy
for addiction.
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Stress/Depression
Stress in humans is defined as bodily or mental tension caused by
physical, mental, or emotional factors.
Stressor exposure promotes the release of hormones from
the adrenal gland, such as corticosterone, epinephrine, and
norepinephrine (NE). The effect of stress on AMPAR
synaptic plasticity is complex and region-specific (McGrath
and Briand, 2019). For example, the administration of
corticosterone to hippocampal neuronal cultures resulted
in time-dependent synaptic accumulation of GluA2-AMPARs,
possibly by increasing GluA2-AMPAR surface diffusion (Groc
et al., 2008). The regulation of AMPARs was biphasic, with
mineralocorticoid receptors (MRs) and glucocorticoid receptors
(GRs) mediating early (minutes) and late (hours) responses
to corticosterone, respectively. The MR-dependent increase in
synaptic AMPAR contents facilitated chemical LTP induction,
while the GR-dependent increase occluded chemical LTP (Groc
et al., 2008; Krugers et al., 2010). This reflected a saturation
process of LTP and also provided a cellular mechanism for the
finding that short bath application of corticosterone (100 nM,
5–10 min) to hippocampal slices enhanced the frequency of
AMPAR miniature excitatory postsynaptic potentials (mEPSC)
in CA1 pyramidal neurons via MRs (Karst et al., 2005), while
within hours, corticosterone slowly increased the amplitude
of AMPAR mEPSC through GRs (Karst and Joëls, 2005) and
impaired synaptic potentiation (Kim and Diamond, 2002;
Zhang et al., 2013). Notably, the antidepressant tianeptine
reversed the corticosterone-induced increase in AMPAR surface
diffusion in hippocampal neurons and restored hippocampal
LTP in slices from acutely stressed mice (Zhang et al., 2013).
This suggests that reversal of AMPAR surface trafficking may
contribute to the restoration of hippocampal synaptic plasticity
in animal models of stress. Other stressful stimuli, such as
NE and emotional stress, induced the phosphorylation and
synaptic delivery of GluA1-AMPARs in hippocampal slice
cultures, which was thought to lower the threshold for LTP
(Hu et al., 2007). It is noteworthy that social defeat stress was
shown to reduce the levels of GluA1-AMPAR in the PFC and
hippocampus, but elevate its levels in NAc (Yang et al., 2016).
Furthermore, stress paradigms that impair hippocampal LTP
have been found to facilitate amygdala LTP (Vouimba et al.,
2004; Suvrathan et al., 2014). This implies that there may be
important region-specific differences in AMPAR regulation and
plasticity that need to be taken into account in the development
of therapeutics.
Interestingly, increasing evidence suggests that stress
facilitates the development of drug addiction. This may be
attributed, at least in part, to stress-induced changes in synaptic
plasticity (Lo Iacono et al., 2018; McGrath and Briand, 2019).
Indeed, drugs of abuse and stress trigger common plasticity
mechanisms in midbrain dopamine neurons. Acute stress and
in vivo administration of drugs of abuse with different molecular
mechanisms both enhanced the AMPAR/NMDAR EPSC ratio at
excitatory synapses onto midbrain dopaminergic neurons (Saal
et al., 2003). Another study found that early stressors such as
repeated maternal separation increased TNF levels in the PFC
and NAc while reducing GluA2 levels in male but not female
rats. Maternally separated male rats display a greater preference
for a cocaine-associated context, which was reversed by the TNF
inhibitor XPro 1595 through normalizing TNF and GluA2 levels
(Ganguly et al., 2019). Notably, chronic stress in humans is
associated with higher rates of depression or depressive episodes
(Kendler et al., 1999). Thus, the implications of these findings
might extend to depression.
Chronic Pain
Chronic pain conditions often have a psychological component
in the form of a persistent sensory memory of the pain state,
associated with fear, anxiety, and cognitive dysfunction. LTP and
LTD in the dorsal horn of the spinal cord and cortical areas,
including the anterior cingulate cortex (ACC), are increasingly
thought to underlie chronic pain (Bliss et al., 2016). In particular,
evidence from genetic and pharmacological studies indicates
that the recruitment of GluA1-AMPARs to the postsynaptic
membrane contributes to the expression of NMDAR-dependent
LTP in the ACC (Toyoda et al., 2007, 2009; Xu et al., 2008;
Li et al., 2010), the pathogenesis of chronic inflammation and
neuropathic pain (Xu et al., 2008; Li et al., 2010), and chronic
visceral pain (Liu et al., 2015; Wang et al., 2015). Analgesic
effects were obtained by inhibiting AMPAR-mediated responses
or reducing the expression of postsynaptic LTP in the ACC (Li
et al., 2010; Chen et al., 2014; Liu et al., 2015; Wang et al., 2015;
Zhuo, 2019).
Epilepsy
Epilepsy is a neurological disorder characterized by recurrent
and unprovoked seizures, reflecting episodic abnormal
synchronized electrical activity in cerebral neuronal networks
(Rogawski, 2013). Imbalanced excitatory and inhibitory synaptic
transmission is thought to contribute to epilepsy pathogenesis
(Bonansco and Fuenzalida, 2016). An elevation of hippocampal
AMPAR levels has been reported in both temporal lobe
epilepsy (TLE) patients and several animal epilepsy models
(Mathern et al., 1998; Lopes et al., 2013). This is supported by a
positron emission tomography (PET) tracer study of AMPARs
([11C]K-2), showing that [11C]K-2 uptake is increased in the
epileptogenic focus of patients with mesial TLE (Miyazaki
et al., 2020). Therapeutic strategies inhibiting AMPA-mediated
currents, e.g., AMPAR antagonists, have been developed to
treat epilepsy. AMPAR antagonists have been shown to alleviate
epileptiform activity in in vitro models and confer protection
from seizures in many animal seizure models (Rogawski, 2013).
In particular, a selective non-competitive AMPAR antagonist,
perampanel, has been clinically used to treat patients with
partial-onset and tonic-clonic seizures (French et al., 2015a,b;
Piña-Garza et al., 2020).
Summary of Addiction, Stress, Chronic
Pain, and Epilepsy Models
Taken together, the available data suggest that region-
and subunit-specific pathological potentiation of AMPAR-
mediated synaptic transmission is a common feature of animal
models of addiction, stress, chronic pain, and epilepsy models
(Figure 1, bottom left panel). In these models, experimental
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inhibition of potentiated AMPAR-mediated transmission, eg.
using AMPAR antagonists or reversal of enhanced synaptic
strength by regulating AMPAR trafficking and redistribution
was able to mitigate addictive behavior, chronic pain, and
epileptic seizures. In contrast, in the following sections, we
review a set of disorders that are characterized by an impaired
LTP or enhanced LTD, which has been associated with
cognitive deficits.
Huntington’s Disease (HD)
Huntington’s disease (HD) is an autosomal dominant inherited
neurodegenerative disease, clinically characterized by cognitive
deficits, psychiatric disturbance, and motor dysfunction. HD
is caused by a mutated form of the huntingtin gene and the
resulting mutant huntingtin protein (Saudou and Humbert,
2016). Increasing evidence suggests that cognitive and psychiatric
disturbances occur in HD gene carriers and HD mouse
models well before classical neuropathology or the onset of
motor symptom, suggesting that the initial development of
the disease results from a cellular dysfunction rather than a
loss of neurons (Lemiere et al., 2004; Solomon et al., 2008).
Various transgenic and knock-in HD mouse models exhibit
impaired hippocampal LTP at the pre- or early-symptomatic
stage (Hodgson et al., 1999; Murphy et al., 2000; Zhang et al.,
2018). Consistently, behavioral studies reveal the deterioration of
hippocampal-associated spatial memory in distinct HD murine
models and patients (Chan et al., 2014; Majerová et al.,
2012). Recent work has shown that AMPAR surface diffusion
is dramatically increased in hippocampal neurons from HD
rodent models. This was attributed to deficient brain-derived
neurotrophic factor (BDNF)–Tropomyosin related kinase B
(TrkB) signaling, which disrupted AMPAR diffusion trapping,
i.e., the interaction between transmembrane AMPA receptor
regulatory proteins (TARPs) and the PDZ-domain scaffold
protein PSD95 (Zhang et al., 2018). The antidepressant tianeptine
improved BDNF synthesis and intracellular transport, reversed
AMPAR surface diffusion, and restored LTP and hippocampus-
dependent memory in different HD mouse models (Zhang et al.,
2018). AMPARpositive allostericmodulators (AMPAkines) have
also been shown to rescue the deficits in synaptic plasticity and
memory in HD mouse models, possibly via upregulating BDNF
(Simmons et al., 2009, 2011).
Alzheimer’s Disease (AD)
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease, clinically characterized by early memory deficits and
progressive loss of higher cognitive functions. The causes of AD
are unclear, but amyloid-β protein (Aβ) and tau are thought to
play a central role in the etiology and pathogenesis. Extracellular
amyloid plaques (composed of Aβ peptides) and intraneuronal
neurofibrillary tangles (composed of tau) are pathological
hallmarks of AD (Bloom, 2014). However, increasing evidence
suggests that AD begins with synaptic failure before overt
neuronal degeneration, which may contribute to the early
memory impairments (Selkoe, 2002; Luscher and Huber, 2010;
Opazo et al., 2018).
ImpairedNMDAR-dependent hippocampal LTP or enhanced
LTD are observed in various transgenic AD animal models
(Mango et al., 2019). Tau protein appears to be involved
in synaptic removal of AMPARs, as clustering of tau fibrils
reduced synaptic abundance of AMPARs (Shrivastava et al.,
2019). Moreover, Tau protein phosphorylation was involved
in a ketamine-induced reduction in surface expression
of AMPARs in hippocampal neurons (Li et al., 2019).
Besides, mGluR-LTD induced by soluble Aβ oligomers is
also thought to contribute to the mental decline in AD
(Luscher and Huber, 2010). This appears to result from
enhanced GluA2/GluA3-AMPAR endocytosis by Aβ oligomers
(Jurado, 2018), which may require the participation of PICK1
(protein interacting with C kinase 1; Alfonso et al., 2014).
Of particular note, Aβ-induced synaptic removal of AMPAR
via endocytosis is necessary and sufficient to induce spine
loss (Hsieh et al., 2006), which is in line with the role of
GluA2-AMPAR in promoting dendritic spine formation and
growth in cultured hippocampal neurons (Saglietti et al.,
2007). This suggests that the dysregulation of AMPAR
trafficking may have both adverse functional and structural
consequences. Moreover, overexpression of the amyloid-
precursor protein (APP) or exposure to Aβ oligomers resulted
in abnormal enhancement of AMPAR surface diffusion
via the activation of GluN2B-containing NMDARs (Opazo
et al., 2018). Immobilizing AMPARs by crosslinking methods
fully rescued spine loss induced by oligomeric Aβ (Opazo
et al., 2018). These lines of evidence suggest that targeting of
AMPAR trafficking may represent a new therapeutic avenue in
AD and HD.
Parkinson’s Disease (PD)
Parkinson’s disease (PD) is another neurodegenerative disorder
associated with loss of dopaminergic neurons of the substantia
nigra projection to the striatum, of major importance for motor
control. The cause of PD is unknown but is believed to involve
both genetic and environmental factors (Kalia and Lang, 2015).
PD is not only characterized by motor symptoms but also
non-motor symptoms, including cognitive impairment (Bernal-
Pacheco et al., 2012; Modugno et al., 2013). The cognitive decline
and dementia in PD have been associated with hippocampal
dysfunction (Svenningsson et al., 2012; Calabresi et al., 2013;
Cosgrove et al., 2015). For example, mutations in PD-associated
E3 ubiquitin ligase Parkin have been associated with juvenile-
onset PD. Parkin regulates synaptic AMPAR endocytosis via
its binding and retention of the postsynaptic scaffold protein,
homer (Cortese et al., 2016; Zhu et al., 2018). The four
common Parkin point mutations (T240M, R275W, R334C,
G430D; Zhu et al., 2018) or Parkin knock-down (Cortese
et al., 2016) impaired this capacity, reduced surface expression
of GluA1- and GluA2-AMPARs, and disrupted glutamatergic
synaptic transmission in hippocampal neurons. It should be
noted that Parkin is primarily involved in mitochondrial
homeostasis (McWilliams and Muqit, 2017). Mitochondria, as
energy centers and calcium buffer organelles, may play an
important role in the regulation of synaptic plasticity (Todorova
and Blokland, 2017). Moreover, PD dementia is considered a
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convergence of α-synuclein, tau, and Aβ pathologies (Irwin
et al., 2013; Shrivastava et al., 2019). As discussed in the
AD section, both tau and Aβ appear to be involved in the
removal of synaptic AMPARs (Jurado, 2018; Li et al., 2019;
Shrivastava et al., 2019). Thus, PD-related dementia might
involve dysregulation of AMPAR trafficking induced by Aβ
and tau.
In addition to PD dementia, the motor deficits of PD
have also been partially attributed to aberrations in AMPAR
plasticity. There is an imbalance in glutamatergic signaling
between the direct pathway spiny projection neurons (dSPNs)
and indirect pathway SPNs (iSPNs), with LTP (hyper AMPAR
signaling) found in iSPNs while LTD (hypo AMPAR signaling)
found in dSPNs (Shen et al., 2008; Fieblinger et al., 2014;
Shields et al., 2017). In general, activity in the direct-
pathway neurons would promote appropriate actions while the
indirect-pathway suppresses unnecessary actions or movements.
Potentiation or loss of inhibition in the indirect-pathway is
thought to contribute to motor dysfunction (Luscher and
Huber, 2010; Shields et al., 2017). In support of this idea, the
AMPAR antagonist, YM90K, was specifically delivered to the
indirect-pathway through the DART (drugs acutely restricted
by tethering) technique, that used HaloTag to capture and
tether drugs to the cell surface. The treatment profoundly
ameliorated motor deficits, such as akinesia in PD animal models
(Shields et al., 2017).
Fragile X Syndrome (FXS)
Fragile X syndrome (FXS) is a neurodevelopmental disorder.
It is the most common inherited cause of intellectual disability
and a prevalent genetic cause of autism spectrum disorder
(ASD; Cheng et al., 2017). FXS results from loss-of-function
mutations in fragile X mental retardation protein (FMRP),
an RNA-binding protein that regulates local translation of
a subset of mRNAs at both presynaptic and postsynaptic
locations in response to mGluR activation (Luscher and
Huber, 2010). One primary consequence of FMRP loss is
the enhancement of mGluR-LTD, which depends on GluA1-
AMPAR endocytosis (Luscher and Huber, 2010; Cheng et al.,
2017). Fmr1 knockoutmice exhibit enhancement ofmGluR-LTD
both in the cerebellum and hippocampus (Luscher and
Huber, 2010). Various mGluR5 antagonists have entered
clinical trials (Berry-Kravis et al., 2018). This strategy aims
at normalizing multiple cellular processes including LTD by
targeting mGluRs rather than by directly interfering with
ionotropic glutamate receptors, which have crucial physiological
functions. However, the clinical efficacy of mGluR5 antagonists
remains to be determined.
Impaired LTP in Fmr1 knockout mice has also been reported
in multiple brain regions, such as the hippocampus (Lauterborn
et al., 2007; Hu et al., 2008), anterior piriform cortex (Larson
et al., 2005), deep-layer visual neocortex (Wilson and Cox, 2007),
and ACC (Zhao et al., 2005; Wang et al., 2008). Restoring the
synaptic delivery of GluA1-containing AMPARs by enhancing
Ras-PI3K-Akt signaling rescued LTP in Fmr1KOmice (Hu et al.,
2008; Lim et al., 2014). This indicates that targeting of AMPAR
trafficking may be a potential therapeutic strategy in FXS.
Summary of AD, HD, PD, and FXS Models
Taken together, the impairment in hippocampal or cortical
LTP or the enhancement in LTD has been associated with
behavioral and cognitive deficits in animal models of AD, HD,
PD, and FXS (Figure 1, bottom right panel). Enhancing AMPAR
diffusion trapping mechanisms (such as with tianeptine),
blocking endocytosis (such as with mGluR5 antagonists), or
enhancing AMPAR function (such as with AMPAR positive
allosteric modulators) have exhibited therapeutic effects, such
as reversal of synaptic plasticity and memory defects in animal
models of AD, HD and FXS. However, the effects of these
strategies in human patients remain to be determined. Brain
region- and AMPAR subunit-specific treatment is needed.
DISCUSSION
While dysregulation of AMPAR synaptic plasticity is emerging as
a point of convergence in multiple pathological pathways across
several brain disorders, it is unlikely to be the major driver of
pathology. Indeed, each brain disorder has a distinct and complex
etiology and pathogenesis. Rather, the pathological impact on
the excitatory synapse directly influences the expression of
the disorders or associated symptoms, and these effects are
reversible. Targeting a converging point of multiple pathological
pathways, especially in early stages of diseases, such as HD and
AD,may bemore efficient than targeting any individual pathway.
In addition, the pathological potentiation and weakening of
synaptic strength both adversely impact the plastic range of the
synapse and thus may hamper further plasticity (metaplasticity).
Therefore, strategies that can preserve the plastic range of the
synapse, eg. regulating AMPAR trafficking, will be beneficial.
In particular, modulating AMPAR trafficking leads to AMPAR
redistribution without perturbing AMPAR function, which is a
great advantage.
Small interfering peptides that target protein-protein
interactions are attracting increasing attention as potential
therapeutics, partly due to their high binding specificity and
affinity, and minimal off-target effects (Fosgerau and Hoffmann,
2015; Havasi et al., 2017). Interfering peptides targeting AMPAR
endocytosis were shown effective in preventing the expression
of D-amphetamine-induced behavioral sensitization and
facilitating the extinction of morphine-induced conditioned
place preference in rodent models of drug addiction (Brebner
et al., 2005; Dias et al., 2012). We propose that peptides
disrupting the diffusion trapping mechanism of AMPARs are
an alternative strategy. Though promising, the therapeutic
application of cell-penetrating peptides in humans remains
challenging (Fosgerau and Hoffmann, 2015; Havasi et al., 2017).
As an alternative, aptamers are oligonucleotide molecules that
bind to a specific target molecule. For example, attempts have
made to design RNA aptamers as AMPAR antagonists (Huang
and Niu, 2019). However, there is still a long way to go to
translate them into drug options.
A better understanding of the molecular mechanism and
dynamics of AMPAR-mediated plasticity may help in the
further identification of therapeutic targets. For dissecting
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mechanisms, the use of light-sensitive proteins allows fast and
reversible manipulation of protein targets with high spatial-
temporal precision (Paoletti et al., 2019). The development
of optogenetic and optopharmacological tools may help to
elucidate the spatial-temporal regulation of AMPAR trafficking
in specific cell types and circuits in animal models. For example,
genetically-encoded protein photosensors such as LOVTRAP
and dimeric Dronpa, have been recently developed (Wang
et al., 2016; Zhou et al., 2017). LOVTRAP can be used
for reversible light-induced protein dissociation. It requires
attaching one of the Zdk/LOV2 pairs to the target protein,
and the other to the membrane (Wang and Hahn, 2016).
Thus, LOVTRAP technology could serve to manipulate the
synaptic anchoring of AMPARs by controlling the interaction
between amembrane TARP and a PDZ-containing protein in the
PSD. Another example is Dronpa, a reversibly photoswitchable
fluorescent protein, which associates and dissociates in response
to 400 nm and 500 nm illumination, respectively (Zhou et al.,
2017). A generalizable method for optical control of kinases
has been recently reported. Photoswitchable kinases, such as
psRaf1, psMEK1, psMEK2, and psCDK5, have been successfully
generated by attaching two photoswitchable dimeric Dronpa
(pdDronpa) domains in the kinase functional domain. The light
switch enables the caging and uncaging of the core kinase
domain with high temporal and spatial precision (Zhou et al.,
2017). This method could be used to elucidate local, synaptic
regulation of AMPARs by protein kinases. Furthermore, a study
successfully used a freely diffusible photoswitchable quinoxaline-
2,3-dione, an antagonist selective for AMPARs, to control action
potential firing optically (Barber et al., 2017). Another study
developed a technique to inactivate synaptic GluA1 AMPARs
in vivo using chromophore-assisted light inactivation and erased
acquired fear memory in the animals (Takemoto et al., 2017).
Thus, optogenetics and optopharmacology emerge as powerful
tools for manipulating and interrogating synaptic plasticity
with high spatial-temporal precision. Because light does not
penetrate tissue easily, applying optogenetic tools in living
animals often requires the implantation of invasive optical fibers
into the brain. This has limited their applications in humans.
Recently, an ultra-sensitive light-responsive molecule, SOUL,
has been developed. Once engineered in the neurons inside
the brain of mice and monkeys, the neurons can be turned
on and off by illumination from outside of the head (Gong
et al., 2020). Such non-invasive approaches hold promise for
therapeutic optogenetics.
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